An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL)
Objective
To evaluate the efficacy of tirabrutinib monotherapy in patients with R/R PCNSL. To evaluate the safety of tirabrutinib monotherapy in patients with R/R PCNSL. To evaluate the PK of tirabrutinib monotherapy in patients with R/R PCNSL.
